About Eko.Ai Pte Ltd. D/B/A Us2.Ai
Us2.ai (Eko.Ai Pte Ltd.) is a medical AI company specializing in automated echocardiography analysis. The company's FDA-cleared and CE-marked platform serves as an AI Echo Copilot that transforms cardiac ultrasound workflows by delivering fully automated echo reporting from DICOM upload to structured clinical report in under two minutes, with zero manual clicks required. The platform addresses critical bottlenecks in echo labs where reporting time limits throughput and specialist availability restricts patient access. Us2.ai's technology performs real-time processing of echocardiograms, automatically generating measurements, disease detection, and clinical findings without requiring frame selection or manual annotations. The system integrates seamlessly with existing infrastructure including ultrasound devices, PACS, CVIS, and EMR systems, available in both cloud and on-premise deployment models. The platform covers multiple cardiac conditions including cardiac amyloidosis (featuring first-of-its-kind AI-powered detection), heart failure, aortic stenosis, pulmonary hypertension, and provides advanced capabilities like strain analysis and stress echocardiography. Clinical evidence demonstrates a 70% reduction in reporting time and approximately 75% faster diagnosis time. Us2.ai serves cardiologists, sonographers, hospitals, and clinical trial core labs across 28+ countries with over 500 hospitals and 1 million scans analyzed. The company has published research in leading journals including Nature Communications, The Lancet Digital Health, European Heart Journal, JACC, and Circulation.
Clinical Focus
Medical conditions and clinical areas addressed by Eko.Ai Pte Ltd. D/B/A Us2.Ai.
Who It Serves
Milestones & Awards
Recent Milestones
First-of-its-kind AI-powered cardiac amyloidosis detection (FDA cleared and CE marked). Over 1 million scans analyzed across 500+ hospitals in 28+ countries. Published in multiple top-tier medical journals.
Awards & Recognition
Featured and covered by The Washington Post. Published in Nature Communications, The Lancet Digital Health, European Heart Journal, JACC, and Circulation.
Key Partnerships
Social & Media
Latest Updates
Inside Endeavor Health's AI Echo Adoption: A Conversation with Dr. Ilya Karagodin
Yesterday
Med Q&A with Us2.ai’s Co-Founder Dr. Carolyn Lam: The Future of AI-Enabled Cardiology
1w ago
Canon Medical Systems USA and Us2.ai Announce Reseller Relationship for AI-Enabled Echocardiography
1w ago
Us2.ai at ASHI 2026: AI echo detects cardiac amyloidosis missed by clinicians
2w ago
Using AI Echo to Detect Cardiac Amyloidosis Early: Us2.ai Webinar with Studycast
2w ago
Company Details
Work here?
Claim this listing to update company information and connect with our audience.
Claim This ListingSecurity & Compliance
Official Sources
Similar Companies in this Market
View all 64 →
AccurKardia
AI-powered platform for cardiovascular disease detection and cardiac risk assessment.
Acorai
AI platform for cardiovascular disease detection and cardiac risk assessment.
Aisap
11-50 employees
AISAP provides FDA-cleared AI-powered diagnostic algorithms embedded in an operating system for point-of-care ultrasound (POCUS) devices. The platform enables rapid, expert-level cardiac imaging interpretation at the bedside, helping physicians detect structural heart disease early and make faster clinical decisions across hospitals, clinics, and screening programs.
AliveCor
AliveCor develops FDA-cleared, AI-powered ECG devices and software platforms for cardiac monitoring. The company offers portable ECG solutions ranging from consumer personal devices to clinical-grade 12-lead systems, serving patients, healthcare providers, biopharma companies, and health systems with remote and connected cardiac care.
Anumana AI
series c · 175 employees
Anumana AI develops and delivers AI-driven ECG algorithms to enable early diagnosis and intervention for cardiovascular conditions.
Artrya
11-50 employees
Artrya develops AI-powered solutions for rapid assessment of chest pain patients in emergency and primary care settings. The company's technology analyzes coronary computed tomography angiography (CCTA) to detect arterial plaque and stratify patient risk within minutes.
Bay Labs
Bay Labs is a health AI company focused on cardiology and cardiovascular health. The company's website is currently under construction with limited public information available.
BunkerHill Health
Bunkerhill Health provides Carebricks, an AI-powered platform that enables health systems to design, deploy, and operationalize AI agents across clinical and operational workflows. The platform reasons across patient data and automates actions within existing EHR systems.
Data Accuracy Notice: Company information on HealthAI Central is compiled from public sources and updated regularly. While we strive for accuracy, details such as funding figures, employee counts, and product offerings may change. We recommend verifying critical information directly with the company before making business decisions.